Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit

被引:98
作者
Nguyen, T. H.
Hoppe-Tichy, T.
Geiss, H. K.
Rastall, A. C.
Swoboda, S.
Schmidt, J.
Weigand, M. A.
机构
[1] Univ Heidelberg Hosp, Dept Pharm, D-69120 Heidelberg, Germany
[2] Univ Heidelberg Hosp, Dept Hyg & Med Microbiol, D-69120 Heidelberg, Germany
[3] Univ Heidelberg Hosp, Dept Surg, D-69120 Heidelberg, Germany
[4] Univ Heidelberg Hosp, Dept Anesthesiol, D-69120 Heidelberg, Germany
关键词
fungal; mycology; drug monitoring;
D O I
10.1093/jac/dkm125
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background. Co-morbidity, medical and surgical interventions often cause alterations to drug plasma concentrations and pharmacokinetic parameters in critically ill patients. In the present study, we investigated parameters influencing plasma caspofungin concentrations in patients of a surgical intensive care unit (SICU). Methods: In a monocentre open study, caspofungin trough concentrations (C-24) were determined for a group of SICU patients. A linear-mixed model was then used to assess factors influencing caspofungin plasma concentrations. Results: A total of 40 SICU patients were enrolled. Age and body weight ranged from 22 to 76 years and 47 to 108 kg, respectively. All participants received a caspofungin loading dose of 70 mg and a maintenance dose of 50 mg/day. The median duration of therapy was 10 days. Caspofungin C-24 in SICU patients varied more than those determined for healthy subjects reported in previous studies (0.52-4.08 mu g/mL versus 1.12-1.78 mu g/mL). According to our model, caspofungin C24 were predicted to be significantly higher in patients with body weight < 75 kg (P = 0.019) and patients with albumin concentration > 23.6 g/L (P = 0.030). Conclusions: Our results show that body weight and albumin concentration influence caspofungin C-24 in SICU patients and should therefore be considered prognostic factors.
引用
收藏
页码:100 / 106
页数:7
相关论文
共 47 条
[1]  
[Anonymous], 2001, BIOAN METH VAL GUID
[2]   Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases [J].
Arathoon, EG ;
Gotuzzo, E ;
Noriega, LM ;
Berman, RS ;
DiNubile, MJ ;
Sable, CA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :451-457
[3]   Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens [J].
Barletta, JF ;
Johnson, SB ;
Nix, DE ;
Nix, LC ;
Erstad, BL .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2000, 49 (05) :869-872
[4]   In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].
Bartizal, K ;
Gill, CJ ;
Abruzzo, GK ;
Flattery, AM ;
Kong, L ;
Scott, PM ;
Smith, JG ;
Leighton, CE ;
Bouffard, A ;
Dropinski, JF ;
Balkovec, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332
[5]   BEHAVIOR OF ANTIBIOTICS DURING HUMAN NECROTIZING PANCREATITIS [J].
BASSI, C ;
PEDERZOLI, P ;
VESENTINI, S ;
FALCONI, M ;
BONORA, A ;
ABBAS, H ;
BENINI, A ;
BERTAZZONI, EM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :830-836
[6]   INFLUENCE OF WEIGHT ON AMINOGLYCOSIDE PHARMACOKINETICS IN NORMAL WEIGHT AND MORBIDLY OBESE PATIENTS [J].
BAUER, LA ;
EDWARDS, WAD ;
DELLINGER, EP ;
SIMONOWITZ, DA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (05) :643-647
[7]   Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: Influence of concomitant liver cirrhosis [J].
Bellmann, R ;
Egger, P ;
Gritsch, W ;
Bellmann-Weiler, R ;
Joannidis, M ;
Dunzendorfer, S ;
Wiedermann, CJ .
ACTA MEDICA AUSTRIACA, 2002, 29 (03) :112-116
[8]   Imipenem levels are not predictable in the critically ill patient [J].
Belzberg, H ;
Zhu, J ;
Cornwell, EE ;
Murray, JA ;
Sava, J ;
Salim, A ;
Velmahos, GC ;
Gill, MA .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2004, 56 (01) :111-117
[9]  
BIRKETT DJ, 2002, PHARMACOKINETICS
[10]   THE ALTERED PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUGS COMMONLY USED IN CRITICALLY ILL PATIENTS [J].
BODENHAM, A ;
SHELLY, MP ;
PARK, GR .
CLINICAL PHARMACOKINETICS, 1988, 14 (06) :347-373